NVO240726C125000
- 3.47
- -5.11-59.56%
Novo-Nordisk A/S Newsroom
UK's NHS Prescribes Weight-Loss Drug Wegovy Less Than Expected Due To Service Shortages
Novo Nordisk Shares Decline Amid Competitive Pressure
Viking Therapeutics Stock Surges 31% As Company Advances Weight Loss Drug To Late-Stage Trial
Novo Nordisk's Wegovy Gets EU Regulator Endorsement to Reduce Heart Risks -- Update
Novo Nordisk Wins EU Backing for Wegovy Label Update
European Equities Traded in the US as American Depositary Receipts Trend Slightly in Thursday Trading
Viking Stock Jumps After Company Speeds Development Its Weight-Loss Pill -- Barrons.com
Novo Nordisk's Options Frenzy: What You Need to Know
Express News | Eli Lilly and Novo Nordisk Shares Are Trading Lower After Competitor Viking Announced the Advancement of Its Obesity Candidate
The “up-and-coming diet drug” Viking (VKTX.US) drug enters the late stages of development, and the “Nolie” stock price fell in shock
As the Viking diet pill entered the later stages of clinical trials, Eli Lilly and Novo Nordisk stock prices declined.
Viking Sends Lilly, Novo Lower as Obesity Drug Enters Late-stage Program
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
Novo Nordisk's (NVO.US) weight-loss drug, Wegovy, has been approved by UK regulatory authorities and can be used to treat heart disease.
Following the United States, the regulatory authority in the United Kingdom has also approved the expansion of the application scope of Novo Nordisk's (NVO.US) weight loss drug Wegovy to treat heart disease.
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
Novo Nordisk's Wegovy Gets UK Approval as Preventative Treatment for Heart Problems in Obese, Overweight Adults
Cytoki Pharma Announces Positive Phase 1 Data Showing Potential of CK-0045 to Improve Cardiometabolic Risk Factors
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
Eli Lilly, Novo Are Weight-Loss Winners. Rivals Won't Be an Issue for Years: Analyst. -- Barrons.com
Novo Nordisk A/S - Share Repurchase Programme
The trend of weight loss drug sector in US stock market is diverging. Novo Nordisk (NVO.US) and Eli Lilly and Co (LLY.US) face challenges to their duopoly.
As more and more pharmaceutical companies enter the lucrative weight loss drug market to get a share of the pie, the increasing competition is making investors worried about the duopoly position of Novo Nordisk and Eli Lilly and Co in this market.